Cargando…

Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study

BACKGROUND: The development of comorbidities has become increasingly relevant with longer-term cancer survival. OBJECTIVE: To assess the pattern of comorbidities among Australian women with breast cancer treated with tamoxifen or an aromatase inhibitor. DESIGN: Retrospective cohort study using Pharm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Huah Shin, Koczwara, Bogda, Roder, David, Niyonsenga, Theo, Vitry, Agnes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885067/ https://www.ncbi.nlm.nih.gov/pubmed/29651409 http://dx.doi.org/10.15256/joc.2018.8.125

Ejemplares similares

Health status and mental distress in people with cancer and comorbid conditions: The Australian National Health Survey analysis
por: Ng, Huah Shin, et al.
Publicado: (2023)

Comorbidities and their management in women with breast cancer—an Australian survey of breast cancer survivors
por: Koczwara, Bogda, et al.
Publicado: (2023)

The effects of comorbidity on colorectal cancer mortality in an Australian cancer population
por: Pule, Maleshwane Lettie, et al.
Publicado: (2019)

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors
por: Heery, Mary
Publicado: (2023)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
por: Sawada, Tomoya, et al.
Publicado: (2023)

Developing a comorbidity index for comparing cancer outcomes in Aboriginal and non-Aboriginal Australians
por: Pule, Lettie, et al.
Publicado: (2018)

Assessment of the therapeutic value of new medicines marketed in Australia
por: Vitry, Agnes I, et al.
Publicado: (2013)

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer
por: Haque, Reina, et al.
Publicado: (2012)

Variations in colorectal cancer pattern of care by age and comorbidity in South Australia
por: Gheybi, Kazzem, et al.
Publicado: (2023)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort
por: Blondon, Marc, et al.
Publicado: (2022)

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
por: Huiart, L, et al.
Publicado: (2011)

Associations of advanced age with comorbidity, stage and primary subsite as contributors to mortality from colorectal cancer
por: Gheybi, Kazzem, et al.
Publicado: (2023)

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients
por: Gremke, Niklas, et al.
Publicado: (2022)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

‘Food for Thought’—The Relationship between Diet and Cognition in Breast and Colorectal Cancer Survivors: A Feasibility Study
por: Coro, Daniel G., et al.
Publicado: (2021)

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
por: Harrigan, Maura, et al.
Publicado: (2021)

Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data
por: Choi, Sung Hyouk, et al.
Publicado: (2020)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
por: Record, Helena, et al.
Publicado: (2023)

Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
por: Park, Jin Young, et al.
Publicado: (2013)

Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors
por: Wang, Tzu-Fei, et al.
Publicado: (2022)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor
por: Jordan, Jennifer H, et al.
Publicado: (2021)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
por: Pineda-Moncusí, Marta, et al.
Publicado: (2020)

Influence of Comorbidities on Therapeutic Progression of Diabetes Treatment in Australian Veterans: A Cohort Study
por: Vitry, Agnes I., et al.
Publicado: (2010)

A higher incidence of smooth endoplasmic reticulum clusters with aromatase inhibitors
por: Saito, Hiroe, et al.
Publicado: (2019)

Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK
por: Bromley, Susan E., et al.
Publicado: (2019)

Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors
por: Zava, David T, et al.
Publicado: (2021)

Rethinking cancer survivorship: the Prostate Cancer Survivorship Essentials Framework
por: Dunn, Jeff, et al.
Publicado: (2021)

Finding My Way from clinical trial to open access dissemination: comparison of uptake, adherence, and psychosocial outcomes of an online program for cancer-related distress
por: Beatty, Lisa, et al.
Publicado: (2022)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer
por: John-Baptiste, Ava A., et al.
Publicado: (2013)

Correction to: Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK
por: Bromley, Susan E., et al.
Publicado: (2019)

Mechanisms of allosteric and mixed mode aromatase inhibitors
por: Souza, Samson A., et al.
Publicado: (2021)

Barriers to employment of Australian cancer survivors living with geographic or socio‐economic disadvantage: A qualitative study
por: Kemp, Emma, et al.
Publicado: (2021)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_evjque8pnfj8enajt7do7cugqk